Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Merck & Company logo

News

Merck to Acquire Cubist Pharmaceuticals: What It Means for Mutual Fund Investors (MRK, CBST)

Shauna O'Brien Dec 08, 2014



Inside the Deal


Cubist focuses on drugs that treat infectious diseases, usually in a hospital setting. According to Cubist, it plans to release four new drugs by 2020. This purchase will allow MRK to continue its strategy to focus on areas including diabetes, acute hospital care, vaccines and oncology.


Mutual Funds to Watch




The Bottom Line


Download Our Free Report

Why 30 trillion is invested in mutual funds book